Foekens J A, Portengen H, van Putten W L, Trapman A M, Reubi J C, Alexieva-Figusch J, Klijn J G
Division of Endocrine Oncology (Biochemistry and Endocrinology) Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Cancer Res. 1989 Dec 15;49(24 Pt 1):7002-9.
The prognostic significance, as well as the relationship with known prognostic factors in breast cancer, of insulin-like growth factor 1 receptor (IGF-1-R), epidermal growth factor receptor (EGF-R), and somatostatin receptor (SS-R) was evaluated. IGF-1-R was positively correlated with estrogen receptor and age, but not significantly with progesterone receptor, lymph node status, and tumor size. EGF-R was negatively correlated to estrogen receptor and progesterone receptor, whereas no association was found with age, lymph node status, and tumor size. The levels of the tumor contents of IGF-1-R and EGF-R were not significantly related to tumor recurrence in 214 patients (test for trend, P = 0.20 and P = 0.08, respectively). However, patients with tumors containing intermediate levels of EGF-R (0.5 to 2.0 fmol/mg of membrane protein) experienced a longer disease-free survival than did patients with tumors possessing lower or higher levels of EGF-R. This effect was most pronounced in the subgroup of patients with positive axillary lymph nodes: 66% disease-free after 5 yr compared with 38% and 46% for the groups with lower and higher EGF-R levels, respectively. The relapse-free survival for patients with tumors containing SS-R (15%) was significantly longer than for patients with SS-R-negative tumors (82% versus 46% disease free after 5 yr, P = 0.04). Assessment by multivariate analysis showed that lymph node status, tumor size, and differentiation grade were independent prognostic factors for relapse. In the Cox model, estrogen receptor and progesterone receptor were both negatively correlated with tumor recurrence, whereas overall EGF-R and IGF-1-R did not show such a relation.
评估了胰岛素样生长因子1受体（IGF-1-R）、表皮生长因子受体（EGF-R）和生长抑素受体（SS-R）在乳腺癌中的预后意义及其与已知预后因素的关系。IGF-1-R与雌激素受体和年龄呈正相关，但与孕激素受体、淋巴结状态及肿瘤大小无显著相关性。EGF-R与雌激素受体和孕激素受体呈负相关，而与年龄、淋巴结状态及肿瘤大小无相关性。214例患者中，IGF-1-R和EGF-R的肿瘤含量水平与肿瘤复发无显著相关性（趋势检验，P值分别为0.20和0.08）。然而，EGF-R水平处于中等（0.5至2.0 fmol/mg膜蛋白）的肿瘤患者的无病生存期长于EGF-R水平较低或较高的患者。这种效应在腋窝淋巴结阳性患者亚组中最为明显：5年后66%无病，而EGF-R水平较低和较高组分别为38%和46%。含有SS-R的肿瘤患者的无复发生存期（15%）显著长于SS-R阴性肿瘤患者（5年后无病率为82%对46%，P = 0.04）。多因素分析评估显示，淋巴结状态、肿瘤大小和分化程度是复发的独立预后因素。在Cox模型中，雌激素受体和孕激素受体均与肿瘤复发呈负相关，而总体EGF-R和IGF-1-R未显示出这种关系。
